Researchers of this study, conducted from January 2021 to January 2023, compared the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) and lean MASLD in patients with plaque psoriasis to a control group undergoing routine physical examinations. Results indicated a higher incidence of MASLD and lean MASLD among patients with psoriasis (43.67% and 10.76%, respectively) compared with the control group (22.15% and 4.43%). After controlling for potential confounding variables, plaque psoriasis was identified as an independent risk factor for MASLD. Serological analysis revealed that patients with psoriasis and MASLD had higher levels of inflammatory markers, tumor marker CYFRA21-1, and increased psoriasis scores compared to those without MASLD, suggesting a synergistic exacerbation of psoriasis conditions by MASLD.

The study highlights the importance of addressing metabolic complications in patients with psoriasis. MASLD was associated with worse psoriasis severity and higher inflammatory markers, emphasizing the need for targeted health education on exercise and diet to mitigate MASLD risks. Elevated CYFRA21-1 levels in MASLD and lean MASLD groups suggest potential involvement in the pathogenesis of both conditions. These findings advocate for comprehensive treatment approaches that include metabolic health management in psoriasis care.

Reference: Lin Z, Shi YY, Yu LY, et al. Metabolic dysfunction associated steatotic liver disease in patients with plaque psoriasis: a case-control study and serological comparison. Front Med (Lausanne). 2024;11:1400741. doi: 10.3389/fmed.2024.1400741.